Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SCNN1A | P37088 | 10/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1428047 | 0.99 | KCNH2 (0.98) | KCNH2CHRM4SCNN1AHDAC3HDAC4 | |
| SCHEMBL11959362 | 0.99 | KCNH2 (1.00) | KCNH2CHRM4SCNN1AHDAC3HDAC4 | |
| SCHEMBL13573271 | 0.98 | KCNH2 (0.98) | KCNH2CHRM4SCNN1AHDAC3HDAC4 | |
| Bromide SCHEMBL1428373 | 0.98 | KCNH2 (0.95) | KCNH2CHRM4SCNN1AHDAC3HDAC4 | |
| SCHEMBL11959350 | 0.97 | KCNH2 (0.95) | KCNH2CHRM4SCNN1AHDAC3HDAC4 | |
| SCHEMBL11959332 | 0.95 | KCNH2 (0.92) | KCNH2CHRM4SCNN1AKDM4ENPC1 | |
| SCHEMBL11959364 | 0.92 | KCNH2 (0.87) | KCNH2SCNN1AHDAC3HDAC4HDAC1 | |
| SCHEMBL13573266 | 0.91 | KCNH2 (0.85) | KCNH2SCNN1AHDAC3HDAC4HDAC1 | |
| SCHEMBL11959374 | 0.91 | KCNH2 (0.84) | KCNH2SCNN1AKDM4ENPC1ALDH1A1 | |
| SCHEMBL13573304 | 0.90 | KCNH2 (0.82) | KCNH2SCNN1AKDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300010-B1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-8236808-B2 | Pyrazine derivatives as ENAC blockers | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20110201625-A1 | Organic Comopunds | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| EP-2300010-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009150137-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201625-A1 | Organic Comopunds | OR10J3, CFTR, CLIC1 | CHRM4 122/4885KCNH2 49/4885SCNN1A 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.